BACKGROUND
Sarcomas are connective tissue-derived malignancies that affect individuals of all ages and occur in any anatomic site of mesodermal origin. Relative to carcinomas and hematologic malignancies, sarcomas are rare, yet disproportionately account for 15-20% of solid cancers in children and young adults. As sarcomas are rare and clinical samples are scarce, pre-clinical animal models and cell lines are needed to further our understanding of sarcoma immunology and to develop effective therapies.
Researchers at the University of Calgary have developed three novel, spontaneous, and synergistic murine sarcoma cell lines with luciferase and mCherry reporters that were developed by extensively backcrossing C57B1/6 mice. The cell lines are a valuable tool for studying bone and soft tissue sarcomas, and for identifying and validating candidate molecular targets and therapeutic applications in sarcoma.
GENOTYPES
- KrasG12D/+; Trp53-/-
- Sarcoma subtype: Undifferentiated pleomorphic sarcoma (UPS)
- Gene editing method: Cre-mediated Trp53 deletion and KrasG12D activation
- Parental mice: Trp53flox and KrasLSL-G12D
- Pten-/-; Trp53-/-
- Sarcoma subtype: Undifferentiated pleomorphic sarcoma (UPS)
- Gene editing method: Cre-mediated Trp53 deletion and Pten deletion
- Parental mice: Trp53flox and Ptenflox
- Pten-/-; Trp53-/-
- Sarcoma subtype: Osteogenic sarcoma
- Gene editing method: Cre-mediated Trp53 deletion and Pten deletion
- Parental mice: Trp53flox and Ptenflox
AREAS OF APPLICATION
- Bone and soft tissue sarcoma research
- Drug identification and screening
COMPETITIVE ADVANTAGES
- Adherent cell lines grow easily in tissue culture using standard media preparation.
- Luciferase and mCherry reporters allow ex-vivo and in-vivo monitoring.
PUBLICATION AND RESOURCES